I'll research BRO (Brown & Brown) before writing the preview. Let me gather recent filings, transcripts, and news.Let me read the most recent earnings materials and gather more context.Let me gather recent news, stock price trends, and the prior-year Q2 comparison base.Let me pull the prior-year Q2 (2025Q2) release for the comparison base, and check recent news via topics/filings.Let me check for analyst consensus estimates and any very recent news.I have enough to write a thorough preview. Let me grab a bit more granular consensus detail.# Brown & Brown (BRO) — Q2 2026 Earnings Preview Reports after the close Monday, July 27, 2026; conference call the following morning
Brown & Brown enters this print as a company in transition — its first full year with the ~$13B Risk Strategies/RSC ("Accession") acquisition in the base, wrestling with a softening property market, and carrying a narrative overhang (a producer-poaching lawsuit, a pharmacy-consulting revenue-model change) that has pushed its organic growth to the bottom of the broker peer group. The debate is no longer about EPS beats — BRO reliably delivers those — but about whether organic growth has troughed and is inflecting higher.
Street expectations (consensus): - Adjusted EPS ~$1.08, up ~5% vs. the year-ago $1.03 - Revenue ~$1.72B, up ~34% year-over-year (Accession-driven; year-ago Q2 was $1.285B) - Full-year 2026 consensus sits near ~$7.1B revenue (+~20%) and ~+6% EPS growth
Note the huge headline growth is almost entirely inorganic — Accession contributes roughly $445M of revenue per quarter. The quality of the print will be judged on organic growth, contingents, and margins, not the reported top-line jump.
The recent organic cadence has been the sore spot: - Q4 2025: organic revenue –2.8%, adjusted EPS $0.93 - Q1 2026: organic flat (0.0%), +2.2% including contingents; adjusted EPS $1.39 (+7.8%); adjusted EBITDAC margin 38.5%
On the Q1 call, management framed 2026 as a "prove-it" year with modest sequential organic improvement each quarter, but capped expectations at an upper bound of ~2.5% in the back half, with the second-half inflection dependent on (1) the legacy "180" business rolling into the organic base within Specialty, and (2) the new retail sales model gaining traction. That makes Q2 a bridge quarter, not the inflection.
The stock reflects the skepticism: BRO is down roughly 12–13% year-to-date (from ~$77.6 in early January to the high-$60s), sold off ~4-5% on the Q1 print in late April and slid toward the mid-$50s by May before recovering. Analyst average price targets sit only modestly above the current price (mid-$70s), and BRO trades at a discount to its historical multiple and to peers — a "show me" valuation.
Management guided to sequential improvement over Q1's flat reading, but with two important caveats for Q2 specifically: - Specialty Distribution: expected to be roughly flat ex-contingents in Q2 due to the heavy weighting of CAT property placements (Q2 is seasonally the biggest property quarter). - Retail: modest improvement, but with a 50–100 bps drag from the pharmacy-consulting revenue-model change (shift from volume-based to per-employee-per-month pricing).
Watch whether consolidated organic pushes convincingly positive (toward 1–2%) or stalls near flat. Anything that reinforces the second-half acceleration thesis (retail net-new-business momentum, 180 rolling into the base) is the bull case; a second consecutive flat-to-negative quarter would pressure the multiple.
This is the biggest external headwind. On the Q1 call, E&S property placements were down 15–35% (and worsening late in the quarter), with coastal property rates back to 2016–17 levels. Because Q2 is property-heavy, the rate drag is at its most acute here. Management flagged it "would not be surprised" if carriers/MGAs got more aggressive on CAT property into wind season — watch commentary on whether rate declines are stabilizing or accelerating, and any early read on June/July renewals.
BRO now reports "organic revenue with contingents" precisely because contingents have become a key stabilizer: when E&S rates fall, underwriting profitability (and thus contingents) tends to rise, since BRO controls the underwriting on its specialty programs. Contingents were up sharply in Q1 (+$54M, ~$22M from Accession), and management guided the full-year total to rise YoY (off a ~$255M base). Strong contingents can keep margins and EPS healthy even with soft core organic — but watch for any moderation signal, and how much of the Q1 strength was one-time (prior-year true-ups).
A start-up competitor (linked to Howden) hired away a group of legacy Risk Strategies producers. As of the end of March, departed accounts represented ~$31M of annualized revenue (up from ~$23M the prior quarter), with a ~$10M in-quarter organic impact in Q1. BRO excludes this "Litigation-Related Impact" from reported organic. Key questions: how much further the lost book grows, whether a Massachusetts TRO is containing defections, and the drag it imposes on Retail organic. Consensus reportedly embeds a larger hit than management has quantified so far, so a contained number could be a modest positive.
Management devoted much of the Q1 call to AI — automating >25% of the submission process in wholesale/programs, policy-checking agents in Retail, and a carrier-billing platform saving 50,000+ hours/year. They frame AI as revenue/margin accretive and argue their <$25K-premium exposure (the most "disruptable" business) is only 1–2% of Retail revenue. Any concrete monetization or margin evidence would help the story; investors remain skeptical of AI as a broker disintermediation risk.
The single most important line to read: management's characterization of the second-half organic ramp (that ~2.5% upper bound) and whether Q2 leaves that intact. With the easy inorganic revenue growth already understood by the market, sentiment turns on organic momentum and the property/contingents dynamic.
Preview based on BRO's Q1 2026 earnings call and release, the Q2/Q4 2025 releases for comparison, consensus data from public sources, and recent price action. Figures are approximate; confirm against the actual release.